{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"To determine the overall prevalence of ALK resistance mechanism in patients with detectable ALK fusion in plasma as determined per plasma NGS","groups":[{"description":"Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)","id":"OG000","title":"ALK-positive NSCLC With Progression"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients with detected ALK fusion","reportingStatus":"POSTED","timeFrame":"32 months","title":"Overall Prevalence of ALK Resistance Mechanism Among Patients With the ALK Fusion","type":"PRIMARY","unitOfMeasure":"Participants"}